"While many stakeholders in the pharma industry are campaigning for a 'soft' exit from the EU, there is a risk that the complexity of the regulatory landscape will increase dramatically if a 'hard' Brexit takes place," said Thomas Beck, Senior Vice President Quality Management at Recipharm, in a May 24, 2018 company statement. "Consequently, we are preparing for all eventualities." As part of its plan to strengthen its organization ahead of Brexit, Recipharm said it plans to recruit more staff in laboratory and regulatory roles to meet the additional analytical, release testing, and administration requirements that are expected. Source: Recipharm